Business Wire

COPD: New Data Support Role of Spiolto® Respimat® as 1st-line Maintenance Therapy and Show Superiority over LABA/ICS

Del

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO® 1&2 indicates that Spiolto® Respimat® provides significant quality of life improvements over Spiriva® Respimat® (tiotropium) or placebo, right from the initial stage when patients first need maintenance therapy.1 These data support the role of Spiolto® Respimat® as a new 1st line maintenance therapy for COPD. In addition the ENERGITO® study shows that the lung function improvement§ with Spiolto® Respimat® (tiotropium/olodaterol) is superior to a steroid-containing therapy (LABA/ICS FDC) in patients with moderate to severe COPD.2

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150928005716/en/

(Photo: Business Wire)

(Photo: Business Wire)

From early in the course of COPD, decreasing lung function makes it more and more difficult for people to breathe. To cope with feeling breathless, patients reduce their activity and change their lifestyles which can lead to a ‘downward spiral’ of their condition.3 This in turn results in a large physical and emotional impact on people living with the disease.4 Providing optimal treatment right from the start of maintenance therapy can give patients the best chance of managing their symptoms, keeping active and maintaining their quality of life.

“These two trials further characterise the relevant benefits Spiolto® Respimat® provides compared to two commonly prescribed maintenance treatments: Spiriva® Respimat® and a LABA/ICS FDC,” said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim. “The lung function and quality of life improvements shown in these trials add to the growing body of evidence supporting the benefit of using Spiolto® Respimat® at the initiation of maintenance therapy for COPD.”

OTEMTO ® 1&2 - data reinforce Spiolto ® Respimat ® benefits as 1 st -line maintenance therapy

A post-hoc analysis of the OTEMTO® 1&2 trials* (NCT01964352/ NCT02006732), presented at ERS for the first time, shows that Spiolto® Respimat® provides a clinically meaningful 4 point improvement in quality of life§§ compared to placebo in COPD patients with GOLD 2 disease.1 In the same patient group, 13% more patients achieved a clinically meaningful improvement in quality of life with Spiolto® Respimat® compared to Spiriva® Respimat® (52.8% compared to 39.2%).5

“With no cure for COPD, improving quality of life is one of the major goals of treatment,” said Dave Singh, Professor of clinical pharmacology and respiratory medicine, University of Manchester. “When many patients are first diagnosed their condition is already declining rapidly. Doing as much as possible, early on, can give patients the best opportunity to maintain a good quality of life for longer. This sub-analysis shows that Spiolto® Respimat® could give patients this opportunity.”

These latest results add to the recently published OTEMTO® 1&2 data in Respiratory Medicine, 6 which show Spiolto® Respimat® provides consistent improvements in lung function, breathlessness and quality of life over Spiriva® Respimat® (tiotropium) or placebo. The data also shows that Spiolto® Respimat® provides a safety profile similar to Spiriva® Respimat® or placebo. Incidence of adverse events (AEs) was broadly similar across treatment groups, with a higher incidence of AEs leading to discontinuation in the placebo groups compared to the treatment groups.6

ENERGITO ® - superior lung function improvements over LABA/ICS FDC

Also presented for the first time, data from ENERGITO® (NCT01969721) show that Spiolto® Respimat® met all lung function endpoints**, which included a 42% improvement in trough FEV1, compared to the twice daily LABA/ICS salmeterol/fluticasone propionate in patients with moderate to severe COPD.2

ICS, or steroid-containing therapies, can be associated with potential serious side-effects and guidelines only recommend the use of these treatments in patients with severe COPD and frequent exacerbations (more than 2 per year).7 Despite this, in clinical practice ICS-based therapies are widely used across all COPD stages even for patients with low exacerbation risk who have less severe COPD. In this respect, the results from ENERGITO® add to data from the large-scale WISDOM study,8 raising questions about whether the benefits of ICS outweigh the potential side-effects associated with this class of treatment.

“ICS-containing therapies certainly have a role in the management of COPD but questions remain regarding when to use these treatments,” said Professor Kai-Michael Beeh, Insaf GmbH Institut für Atemwegs-forschung, Wiesbaden, Germany. “The ENERGITO® results further support the potential benefit of Spiolto® Respimat® as a COPD maintenance therapy and the notion that steroid-containing therapies may only be required in a population of patients with more severe stages of the disease and frequent exacerbations.”

The OTEMTO® 1&2 and ENERGITO® trials are part of the >15,000 patient TOviTO® Phase III clinical trial programme investigating the efficacy and safety of Spiolto® Respimat® in COPD. The results build on the pivotal phase III TONADO® trials that demonstrated Spiolto® Respimat® provides significant improvements in lung function, breathlessness, quality of life and reduction in rescue medication use over Spiriva® Respimat® right from the initial disease stages when patients first need maintenance therapy.9,10 Data also showed that Spiolto® Respimat® was well tolerated with a favourable safety profile that was similar to tiotropium or olodaterol alone.9

For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/28_september_2015_copd.html

_______________________

* Results are derived from a post-hoc subgroup analysis of patients with moderate COPD (GOLD stage 2). The primary endpoints of the OTEMTO® studies were: FEV1 AUC0-3, trough FEV1, SGRQ total score in patients with moderate to severe COPD (GOLD stage 2–3)

Chronic obstructive pulmonary disease

§ FEV1 AUC0-12 response (primary endpoint), FEV1 AUC0-24, FEV1 AUC12-24 and trough FEV1 (secondary endpoint), all measured at 6 weeks

‡ long acting beta2 agonist/inhaled corticosteroid fixed dose combination (FDC)

§§ As measured by the St George’s Respiratory Questionnaire (SGRQ)

** FEV1 AUC0-12 response (primary endpoint), FEV1 AUC0-24, FEV1 AUC12-24 and trough FEV1 (secondary endpoint), all measured at 6 weeks

 

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Kristin Jakobs
Phone: +49 6132 77 144553
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Loxam Announces a Conditional Agreement to Acquire UK Platforms20.7.2018 14:51Pressemelding

Loxam Group (“Loxam”) announces that its wholly-owned subsidiary Nationwide Platforms Limited (“Nationwide”) has entered into a conditional agreement with HSS Hire Group plc (“HSS”) with respect to the acquisition of UK Platforms Limited (“UKP”). UKP specializes in renting powered access equipment from its 12 branches located throughout the United Kingdom. The company has approximately 130 employees and operates a fleet of 3,000 units. UKP is controlled by HSS since 2013. As part of this transaction, Nationwide has entered into a commercial agreement with HSS to provide powered access equipment to complement HSS’ existing fleet. The closing of the transaction is subject to the approval by HSS’ shareholders and the confirmation that it will not be referred to the Competition and Mergers Authority. The transaction is expected to close before year end 2018. Don Kenny, CEO of Loxam’s Powered Access Division states: “I am delighted with the acquisition of UKP which will further reinforce NW

Schlumberger Announces Second-Quarter 2018 Results20.7.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2018 Mar. 31, 2018 Jun. 30, 2017 Sequential Year-on-year Revenue $8,303 $7,829 $7,462 6% 11% Pretax operating income $1,094 $974 $950 12% 15% Pretax operating margin 13.2% 12.4% 12.7% 75 bps 45 bps Net income - GAAP basis $430 $525 $(74) -18% n/m Net income, excluding charges & credits* $594 $525 $488 13% 22% Diluted EPS - GAAP basis $0.31 $0.38 $(0.05) -18% n/m Diluted EPS, excluding charges & credits* $0.43 $0.38 $0.35 13% 23% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. n/m = not meaningful Schlumberger Chairman and CEO Paal Kibsgaard commented, “The second quarter was both busy and exciting for Schlumberger as we completed a number of major milestones in preparation for the broad-based global activity upturn that is now emerging. We delivered solid top-line gro

H.I.G. Capital Announces the Sale of KidsFoundation19.7.2018 19:50Pressemelding

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €21 billion of equity capital under management, announced today that one of its affiliates has entered a definitive agreement to sell the KidsFoundation Group (“KidsFoundation”), the Dutch market leader in childcare services, to Onex Corporation (“Onex”)(TSX:ONEX). Terms were not disclosed. Headquartered in Almere, the Netherlands, KidsFoundation provides high-quality childcare to nearly 30,000 children between the ages of six weeks and 12 years. H.I.G. created KidsFoundation in 2014 through the acquisition of assets from the estate of Estro Group. During H.I.G.’s ownership, the company has developed strongly with significant capital invested by H.I.G. to create a high-quality childcare offering. H.I.G. worked with KidsFoundation management to optimise the footprint of the company by exiting loss-making locations, introduce new IT systems to drive operational improvement and develop an internal M&

SIG Combibloc Group Holdings S.à r.l.: 2018 Second Quarter Results19.7.2018 16:01Pressemelding

We are pleased to announce our quarterly conference call to discuss the results of SIG Combibloc Group Holdings S.à r.l. for the second quarter ended June 30, 2018. Date: Monday, July 23, 2018 Time: 15.00 CEST / 14.00 BST / 9.00 EDT The call information will be distributed on our secure site. If you would like access to our call, please contact investor.relations@sig.biz . Regards, SIG Combibloc Group Holdings S.à r.l. View source version on businesswire.com: https://www.businesswire.com/news/home/20180719005634/en/ Contact information SIG Combibloc Group Holdings S.à r.l. Jennifer Gough investor.relations@sig.biz

NEORIS Announces Creation of Innovation Labs Worldwide to Create a Smarter Future19.7.2018 15:32Pressemelding

NEORIS, a global digital consulting services company, announced today it is consolidating the most innovative solutions it has developed in different geographies and allocating unprecedented resources to deploy a network of Innovation Labs worldwide. The main objective is to lay the foundation for the continuous development of disruptive solutions for its four core industries: Manufacturing, Financial Services, Healthcare and Telecommunications. Due to its disruptive nature, NEORIS decided that its first Innovation Lab should be housed in the Monterrey Digital Hub, which today is the first-of-its-kind as it is a space where entrepreneurs, companies, universities and investors converge to foster an ecosystem for Digital Transformation. The lab inaugurated in Monterrey, Mexico is the first of a series of Innovation Labs that will open in the different countries that NEORIS operates, and is a space where customers can experience emerging technologies through real-life scenarios. One such

CORRECTING and REPLACING Albar Capital Deploys FlexNOW19.7.2018 15:29Pressemelding

Subhead of release should read: Out-of-the-Box Multi-Asset Execution Management System (instead of Easy-to-Install Multi-Asset Execution Management System). The corrected release reads: ALBAR CAPITAL DEPLOYS FLEXNOW Out-of-the-Box Multi-Asset Execution Management System FlexTrade (@FlexTrade) today announced that Albar Capital Ltd., a new hedge fund led by Javier Velazquez (formerly of Millennium Capital Partners LLP), is now trading equities and futures using FlexNOW, FlexTrade’s new execution management system. “The FlexNOW team was instrumental in solving several of our problems,” said Jason Ruder, Trader at Albar Capital. “Not only are they helping us with our compliance requirements, they are also responsive to requests that improve my workflow.” According to Rhyd Lewis, FlexNOW Product Manager, FlexNOW’s quick onboarding and easy installation process was critical for Albar Capital’s launch on 2 July. “We had no problem integrating FlexNOW with Albar’s portfolio and risk managemen